Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials.
about
Methodology to assess clinical liver safety dataEvaluation of the cohort size in phase I dose escalation trials based on laboratory data.A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working groupA Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials
P2860
Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Laboratory data in healthy vol ...... ts in Phase I clinical trials.
@ast
Laboratory data in healthy vol ...... ts in Phase I clinical trials.
@en
type
label
Laboratory data in healthy vol ...... ts in Phase I clinical trials.
@ast
Laboratory data in healthy vol ...... ts in Phase I clinical trials.
@en
prefLabel
Laboratory data in healthy vol ...... ts in Phase I clinical trials.
@ast
Laboratory data in healthy vol ...... ts in Phase I clinical trials.
@en
P2093
P356
P1476
Laboratory data in healthy vol ...... ts in Phase I clinical trials.
@en
P2093
Bienvenu J
Guillaumont M
Massignon D
P2888
P356
10.1007/S002280050586
P577
1999-03-01T00:00:00Z
P5875
P6179
1032859848